Quarterly report pursuant to Section 13 or 15(d)

REVENUES (Details 2)

v3.19.3
REVENUES (Details 2) - Sales Revenue, Net [Member] - Customer Concentration Risk [Member]
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
AmerisourceBergen Specialty Group [Member]        
Entity Wide Revenue Major Customer [Line Items]        
Concentration risk, percentage 62.00% 90.00% 60.00% 88.00%
McKesson Plasma and Biologics LLC [Member]        
Entity Wide Revenue Major Customer [Line Items]        
Concentration risk, percentage 22.00% 4.00% 21.00% 3.00%